Almirall S.A. stock (ES0157097017): Dermatology leader reports steady growth

Almirall S.A., a Spanish dermatology specialist, continues to advance its pipeline with key approvals and partnerships. The stock has shown resilience amid European market volatility, offering exposure to the growing skincare sector for US investors.

Almirall S.A. recently highlighted progress in its dermatology portfolio, including regulatory advancements for new treatments targeting inflammatory skin conditions. The company, listed on the Spanish stock exchange, maintains a focus on innovative therapies for psoriasis and atopic dermatitis, areas with rising demand globally. This update underscores Almirall's commitment to R&D amid competitive pressures in biotech.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Almirall S.A.
• Sector/industry: Healthcare / Dermatology
• Headquarters/country: Spain
• Core markets: Europe, US, emerging markets
• Key revenue drivers: Prescription dermatology drugs
• Home exchange/listing venue: Bolsa de Madrid (ALM)
• Trading currency: EUR

Almirall S.A.: core business model

Almirall S.A. operates as a pharmaceutical company dedicated to dermatology, developing and commercializing treatments for skin diseases. Founded in 1944 and headquartered in Barcelona, Spain, it focuses on moderate-to-severe conditions like psoriasis, atopic dermatitis, and actinic keratosis. The business model centers on a mix of marketed products and a robust R&D pipeline, with revenue primarily from Europe but expanding into the US and other regions. This specialization positions Almirall in a niche with high barriers to entry due to clinical expertise required.

The company's flagship product, Ebglyss (lebrikizumab), targets moderate-to-severe atopic dermatitis and has gained traction following European approvals. Almirall invests around 20% of sales in R&D, supporting late-stage assets and early innovations in oncology and respiratory areas, though dermatology remains core. For US investors, Almirall offers exposure to the $15 billion global dermatology market, projected to grow at 8% CAGR through 2030 per IQVIA as of 2025.

Main revenue and product drivers for Almirall S.A.

Revenue is driven by established drugs like Skilarence (dimethyl fumarate) for psoriasis and Solaraze (diclofenac) for actinic keratosis, generating steady cash flows. Ebglyss, licensed from Eli Lilly, represents growth potential with recent launches in key markets. In 2024 full-year results published February 2025, Almirall reported €1.02 billion in sales, up 8% year-over-year, with core dermatology products contributing 85%, according to company IR as of 28.02.2025.

Pipeline catalysts include phase 3 readouts for new indications and geographic expansions. Partnerships bolster development, such as collaborations with Sanofi on respiratory assets. US market access via partnerships enhances relevance, as American patients represent 40% of global dermatology spend, linking Almirall to familiar healthcare dynamics for US portfolios.

Industry trends and competitive position

The dermatology sector benefits from biologics innovation and rising chronic disease prevalence, with atopic dermatitis affecting 15% of children in developed markets. Competitors like AbbVie (Humira successors) and Leo Pharma vie for share, but Almirall differentiates via IL-13 inhibitors like Ebglyss, offering efficacy in head-to-head trials. Market data shows biologics capturing 30% of psoriasis prescriptions by 2025, per EvaluatePharma as of 2024.

Almirall's mid-cap status allows agility versus giants, with a 2024 EBITDA margin of 22% reflecting operational efficiency. European base provides cost advantages, while US listings of peers facilitate benchmarking for American investors tracking biotech trends.

Why Almirall S.A. matters for US investors

Almirall provides US investors indirect exposure to Europe's pharma innovation without direct ADR listing, via Madrid trading accessible through major brokers. Its dermatology focus aligns with US trends in biologics, where similar drugs generate billions. Currency hedging and dividend yields (around 2-3%) add appeal amid Eurozone stability.

With US partnerships and pipeline eyeing FDA pathways, Almirall ties into familiar regulatory scrutiny, offering diversification from pure US biotech volatility.

Conclusion

Almirall S.A. stands as a focused dermatology player with a solid product base and promising pipeline. Recent developments signal continued momentum in core markets, while strategic expansions enhance long-term prospects. Investors monitoring European healthcare will note its niche positioning and growth trajectory.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.